181 related articles for article (PubMed ID: 38418883)
1. An atlas of epithelial cell states and plasticity in lung adenocarcinoma.
Han G; Sinjab A; Rahal Z; Lynch AM; Treekitkarnmongkol W; Liu Y; Serrano AG; Feng J; Liang K; Khan K; Lu W; Hernandez SD; Liu Y; Cao X; Dai E; Pei G; Hu J; Abaya C; Gomez-Bolanos LI; Peng F; Chen M; Parra ER; Cascone T; Sepesi B; Moghaddam SJ; Scheet P; Negrao MV; Heymach JV; Li M; Dubinett SM; Stevenson CS; Spira AE; Fujimoto J; Solis LM; Wistuba II; Chen J; Wang L; Kadara H
Nature; 2024 Mar; 627(8004):656-663. PubMed ID: 38418883
[TBL] [Abstract][Full Text] [Related]
2. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
Fujimoto J; Nunomura-Nakamura S; Liu Y; Lang W; McDowell T; Jakubek Y; Ezzeddine D; Kapere Ochieng J; Petersen J; Davies G; Fukuoka J; Wistuba II; Ehli E; Fowler J; Scheet P; Kadara H
Int J Cancer; 2017 Oct; 141(8):1589-1599. PubMed ID: 28653505
[TBL] [Abstract][Full Text] [Related]
3. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
[TBL] [Abstract][Full Text] [Related]
4. Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.
Yang M; Shen H; Flodby P; Koss MD; Bassiouni R; Liu Y; Jashashvili T; Neely A; Ogbolu E; Castillo J; Stueve TR; Mullen DJ; Ryan AL; Carpten J; Castaldi A; Wallace WD; Zhou B; Borok Z; Marconett CN
Cell Rep; 2023 Dec; 42(12):113286. PubMed ID: 37995179
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
6. p53 governs an AT1 differentiation programme in lung cancer suppression.
Kaiser AM; Gatto A; Hanson KJ; Zhao RL; Raj N; Ozawa MG; Seoane JA; Bieging-Rolett KT; Wang M; Li I; Trope WL; Liou DZ; Shrager JB; Plevritis SK; Newman AM; Van Rechem C; Attardi LD
Nature; 2023 Jul; 619(7971):851-859. PubMed ID: 37468633
[TBL] [Abstract][Full Text] [Related]
7. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform.
Naranjo S; Cabana CM; LaFave LM; Romero R; Shanahan SL; Bhutkar A; Westcott PMK; Schenkel JM; Ghosh A; Liao LZ; Del Priore I; Yang D; Jacks T
Genes Dev; 2022 Aug; 36(15-16):936-949. PubMed ID: 36175034
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A; Odintsov I; Markov V; Caeser R; Sobczuk P; Tischfield SE; Bhanot U; Vanderbilt CM; Cheng EH; Drilon A; Riely GJ; Lockwood WW; de Stanchina E; Tirunagaru VG; Doebele RC; Quintanal-Villalonga Á; Rudin CM; Somwar R; Ladanyi M
J Thorac Oncol; 2023 Sep; 18(9):1165-1183. PubMed ID: 37182602
[TBL] [Abstract][Full Text] [Related]
9. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
10. Club cells employ regeneration mechanisms during lung tumorigenesis.
Chen Y; Toth R; Chocarro S; Weichenhan D; Hey J; Lutsik P; Sawall S; Stathopoulos GT; Plass C; Sotillo R
Nat Commun; 2022 Aug; 13(1):4557. PubMed ID: 35931677
[TBL] [Abstract][Full Text] [Related]
11. Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells.
Dost AFM; Moye AL; Vedaie M; Tran LM; Fung E; Heinze D; Villacorta-Martin C; Huang J; Hekman R; Kwan JH; Blum BC; Louie SM; Rowbotham SP; Sainz de Aja J; Piper ME; Bhetariya PJ; Bronson RT; Emili A; Mostoslavsky G; Fishbein GA; Wallace WD; Krysan K; Dubinett SM; Yanagawa J; Kotton DN; Kim CF
Cell Stem Cell; 2020 Oct; 27(4):663-678.e8. PubMed ID: 32891189
[TBL] [Abstract][Full Text] [Related]
12. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
13. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
Li HS; Liu CM; Wang Y
Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
[TBL] [Abstract][Full Text] [Related]
14. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
15. Alveolar progenitor cells and the origin of lung cancer.
Sainz de Aja J; Dost AFM; Kim CF
J Intern Med; 2021 May; 289(5):629-635. PubMed ID: 33340175
[TBL] [Abstract][Full Text] [Related]
16. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming.
Juul NH; Yoon JK; Martinez MC; Rishi N; Kazadaeva YI; Morri M; Neff NF; Trope WL; Shrager JB; Sinha R; Desai TJ
Nature; 2023 Jul; 619(7971):860-867. PubMed ID: 37468622
[TBL] [Abstract][Full Text] [Related]
17. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
Arnal-Estapé A; Cai WL; Albert AE; Zhao M; Stevens LE; López-Giráldez F; Patel KD; Tyagi S; Schmitt EM; Westbrook TF; Nguyen DX
Oncogene; 2020 Apr; 39(18):3726-3737. PubMed ID: 32157212
[TBL] [Abstract][Full Text] [Related]
18.
Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y
EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704
[TBL] [Abstract][Full Text] [Related]
19. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma.
Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P
Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309
[TBL] [Abstract][Full Text] [Related]
20. EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS
Pribluda A; Daemen A; Lima AN; Wang X; Hafner M; Poon C; Modrusan Z; Katakam AK; Foreman O; Eastham J; Hung J; Haley B; Garcia JT; Jackson EL; Junttila MR
Elife; 2022 Aug; 11():. PubMed ID: 35983994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
